PHARMACOLOGICAL STUDIES OF ANTITUMOR & ANTI-HIV AGENTS
PHARMACOLOGICAL STUDIES OF ANTITUMOR & ANTI-HIV AGENTS
批准号:
3610244
负责人:
ROBERT A NEWMAN
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
1991
资助国家:
美国
项目状态:
已结题
起止时间:
1991-11-15 至 1994-11-30
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI:
--
发表时间:
1994-05
期刊:
Drug metabolism and disposition: the biological fate of chemicals
影响因子:
--
作者:
[R. Newman;A. Fuentes;J. Covey;J. Benvenuto]
通讯作者:
R. Newman;A. Fuentes;J. Covey;J. Benvenuto
High-performance liquid chromatographic measurement of the novel anti-HIV agent 7,8-dihydrocostatolide (NSC 661123).
新型抗 HIV 药物 7,8-二氢木香内酯 (NSC 661123) 的高效液相色谱测定。
DOI:
10.1016/0378-4347(94)00194-4
发表时间:
1994
期刊:
Journal of chromatography. B, Biomedical applications
影响因子:
--
作者:
[Newman,RA, Costa,M, Cisneros,A]
通讯作者:
Cisneros,A
BIOCHEMICAL AND MECHANSIMS OF ACTION OF STUDIES WITH
-
批准号:3609376
-
项目类别:
-
资助金额:$11.89万
-
财政年份:1992
-
负责人:ROBERT A NEWMAN
-
依托单位:
BIOCHEMICAL AND MECHANSIMS OF ACTION OF STUDIES WITH
-
批准号:3609377
-
项目类别:
-
资助金额:$0.0万
-
财政年份:1992
-
负责人:ROBERT A NEWMAN
-
依托单位:
PHARMACOLOGICAL STUDIES OF ANTITUMOR & ANTI-HIV AGENTS
-
批准号:3610242
-
项目类别:
-
资助金额:$0.97万
-
财政年份:1991
-
负责人:ROBERT A NEWMAN
-
依托单位:
PHARMACOLOGICAL STUDIES OF ANTI-TUMOR/HIV AGENTS
-
批准号:3610233
-
项目类别:
-
资助金额:$3.42万
-
财政年份:1991
-
负责人:ROBERT A NEWMAN
-
依托单位:
PHARMACOLOGICAL STUDIES OF ANTI-TUMOR/HIV AGENTS
-
批准号:3610237
-
项目类别:
-
资助金额:$1.73万
-
财政年份:1991
-
负责人:ROBERT A NEWMAN
-
依托单位:
PHARMACOLOGICAL STUDIES OF ANTITUMOR & ANTI-HIV AGENTS
-
批准号:3610243
-
项目类别:
-
资助金额:$1.06万
-
财政年份:1991
-
负责人:ROBERT A NEWMAN
-
依托单位:
PHARMACOLOGICAL STUDIES OF ANTI-TUMOR/HIV AGENTS
-
批准号:3610239
-
项目类别:
-
资助金额:$3.44万
-
财政年份:1991
-
负责人:ROBERT A NEWMAN
-
依托单位:
PHARMACOLOGICAL STUDIES OF ANTI-TUMOR/HIV AGENTS
-
批准号:3610236
-
项目类别:
-
资助金额:$0.0万
-
财政年份:1991
-
负责人:ROBERT A NEWMAN
-
依托单位:
BLEOMYCIN MEDIATED PULMONARY TOXICITY
-
批准号:4691055
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:ROBERT A NEWMAN
-
依托单位:
CORE--BIOCHEMICAL PHARMACOLOGY LABORATORY
-
批准号:4690921
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:ROBERT A NEWMAN
-
依托单位:
海外基金